Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Researchers assessed the efficacy and safety of using lithium for coronavirus disease 2019 (COVID-19) treatment.

5 May 2022

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

In a new study, researchers assessed the efficacy of a third dose of COVID-19 vaccine in anti-CD20 antibody-treated individuals.

4 May 2022

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

28 Apr 2022

Study determines how much U.S. hospitals mark up the price of cancer therapies

U.S. spending on cancer therapies has risen sharply in recent years. Researchers from Brigham and Women's Hospital analyzed data on drug pricing from 61 National Cancer Institute-designated cancer centers to determine how much U.S. hospitals mark up the price of cancer therapies for patients with private health insurance.

24 Apr 2022

Single-cell atlas of non-hematopoietic cells provides insights into lymphoma stromal biology

Researchers from the University of Tsukuba identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of lymphomas.

21 Apr 2022

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

In this interview, News-Medical speaks to Professor Jun Huang about CAR T-cell therapy and its future as a potential treatment for cancer or HIV.

20 Apr 2022

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell immune responses in 93 percent of patients with B-cell deficiencies, including many patients with leukemia and lymphoma, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

12 Apr 2022

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Yale scientists uncover key regulator of body weight. Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.

11 Apr 2022

Study finds higher risk of all-cause mortality among pediatric cancer patients in LMICs during the pandemic

During the first nine months of the COVID-19 pandemic, pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries, according to data presented at the AACR Annual Meeting 2022, held April 8-13.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Vitamin C may help to counteract common side effect of the chemotherapy drug

A study conducted in rats suggests that taking vitamin C may help to counteract the muscle atrophy that is a common side effect of the chemotherapy drug doxorubicin.

4 Apr 2022

Penn researchers generate functional CAR T cells with enhanced anti-tumor potency in 24 hours

A new approach from Penn Medicine researchers could cut the time it takes to alter patients' immune cells for infusion back into the body to find and attack cancer.

29 Mar 2022

Potential new therapeutic target for pancreatic cancer discovered

Northwestern Medicine investigators have discovered that targeting the G alpha 13 protein in pancreatic tumors promotes tumor growth and progression, according to a study published in Cell Reports.

29 Mar 2022

Japanese researchers discover new mechanisms of action by extracellular vesicles in lymphoma

Japanese collaborative research teams have discovered new mechanisms of action by extracellular vesicles (EV) for the development and malignant progression of lymphomas.

28 Mar 2022

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Researchers identified the recombination of two SARS-CoV-2 variants.

28 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

New implantable biotechnology produces and releases CAR-T cells for attacking tumors

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.

24 Mar 2022

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Researchers have determined the effect of booster immunization on the levels of antibodies generated, against SARS-CoV-2 variants, including the Omicron strain, in cancer patients with or without active B cell-targeted therapy.

22 Mar 2022

Lymphoma News and Research

Further Reading

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

Study determines how much U.S. hospitals mark up the price of cancer therapies

Single-cell atlas of non-hematopoietic cells provides insights into lymphoma stromal biology

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

New COVID-19 vaccine induces T-cell immune responses in most patients with B-cell deficiencies

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Study finds higher risk of all-cause mortality among pediatric cancer patients in LMICs during the pandemic

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Vitamin C may help to counteract common side effect of the chemotherapy drug

Penn researchers generate functional CAR T cells with enhanced anti-tumor potency in 24 hours

Potential new therapeutic target for pancreatic cancer discovered

Japanese researchers discover new mechanisms of action by extracellular vesicles in lymphoma

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

New implantable biotechnology produces and releases CAR-T cells for attacking tumors

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News